Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference
Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT. The event will be accessible via live webcast through the company's website, with an archived replay available for 90 days post-conference. Kezar focuses on innovative therapies for autoimmune diseases and cancer, with candidates like KZR-616 and KZR-261 in development.
Details
News Market Reaction – KZR
The recorded move for KZR in the trading session of this news was -9.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will participate in a Fireside Chat during the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30pm EDT.
The presentation will be webcast live and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from Kezar’s protein secretion program, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.
CONTACT:
Celia Economides
IR@kezarbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.